We are Sorry, This Page doesn't Exist

Bristol-Myers Squibb Co. shares rose 0.9% after the company beat earnings estimates but lowered its full-year per-share earnings guidance. The New York-based drug company said it had net income of $1.353 billion,.....»»

Bristol-Myers (BMY) Q1 earnings and sales beat estimates on strong perfor.....»»

Bristol-Myers (BMY) beat estimates on both counts. Bristol-Myers Squibb Company BMY is a.....»»

Shares of Bristol-Myers Squibb gained 2.6% in premarket trading on Thursday after the drugmaker posted stronger-than-ex.....»»

Bristol-Myers Squibb (NYSE: BMY) reported third-quarter earnings of $1.17 per share Thursday, beating the analyst consensus estimate of $1.07.  The company reported quarterly sales of $6.007 billion.....»»

Zacks.....»»

Bristol-Myers (BMY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Want the latest recommendations from Zacks Inve.....»»

The big drugmaker beat Wall Street estimates in the first quarter thanks to solid sales growth for its top blockbusters......»»

Bristol-Myers (BMY) delivered earnings and revenue surprises of 0.92% and 2.09%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock? Want the latest recommendations from Zacks Inve.....»»

Bristol-Myers (BMY) is scheduled to report second-quarter earnings on Jul 26.....»»

Bristol-Myers (BMY) beats estimates on both counts in the second quarter. Eliquis and Opdivo continue to record solid sales. Bristol-Myers Squibb Company’s BMY second-quarter 2018 earnings of $1.01 per share exceeded the Zacks Consensu.....»»

Merck & Co beat quarterly profit estimates on Friday as sales of its blockbuster drug Keytruda overtook rival Bristol-Myers Squibb's Opdivo, but that was not enough for investors who expected bigger gains in market share for the cancer therapy......»»

Bristol-Myers (BMY) beats earnings estimates in the third quarter but misses sales expectation by a slight margin. Eliquis and Opdiv.....»»

Bristol-Myers Squibb Co. said Thursday it expects to achieve per-share earnings of $3.75 to $3.85 for 2019, excluding any benefits from its takeover of Celgene Corp. announced earlier. Adjusted EPS is expected to range from $4.10 to $4.20, whi.....»»

Bristol-Myers Squibb reported better-than-expected quarterly results before the markets opened on Thursday......»»

The Goldman Sachs Group, Inc.'s (NYSE: GS) first-quarter 2024 earnings per share of $11.58 surpassed the Zacks Consensus Estimate of $8.54. Also, the bottom line increased .....»»

On Tuesday, Johnson & Johnson (NYSE:JNJ) reported first-quarter adjusted EPS of $2.71, up 12.4% year over year, beat.....»»

Palo Alto Networks Inc. shares rose in the extended session Thursday after the cybersecurity company reported results that topped Wall Street estimates and hiked its outlook for the year......»»

BJ's Wholesale Club Holdings Inc. shares slid 4% in premarket trade Thursday, after the company beat estimates for the first quarter but declined to.....»»

Biotech stocks had a volatile ride in the week ended May 14, with stocks moving broadly lower for much of the week before coming back up strongly in the final session. Some of the weakness may be traced back to the across-t.....»»